NCT06666348View on ClinicalTrials.gov

Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

April 30, 2030

Study Completion Date

April 30, 2033

Conditions

Pediatric Low-grade Glioma

Interventions

DRUG

Mirdametinib

Participants will receive orally administered mirdametinib in combination with intravenous vinblastine chemotherapy

Trial Locations (1)

H3T 1C5

CHU Sainte-Justine, Montreal

All Listed Sponsors

lead

St. Justine's Hospital

OTHER

NCT06666348 - Phase 1/2 Study of Mirdametinib + Vinblastine for Newly Diagnosed/Previously Untreated PLGG + Activation of MAPK | Biotech Hunter | Biotech Hunter